Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., (NYSE: PEN) announce the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion. Penumbra offers innovative mechanical thrombectomy products for use in peripheral vascular procedures to remove blood clots causing blockages in arterial, venous and pulmonary vessels, including the Lightning Bolt® and Lightning Flash® computer assisted vacuum thrombectomy (CAVT™) systems.
Read the full article: Boston Scientific Announces Agreement to Acquire Penumbra, Inc. //
Source: https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-penumbra-inc-302662041.html